Wednesday, September 10, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Cancer

PALOMA-2 Study Reveals High Response Rates with Monthly Subcutaneous Amivantamab Combined with Lazertinib in EGFR-Mutated NSCLC

September 9, 2025
in Cancer
Reading Time: 4 mins read
0
65
SHARES
591
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

In a significant advancement for the treatment of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations, newly presented data from the PALOMA-2 trial illuminate the clinical potential of a novel dosing regimen combining subcutaneous amivantamab administered once every four weeks with daily oral lazertinib. This innovative approach, shared at the 2025 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer (IASLC), provides encouraging evidence that less frequent dosing schedules can sustain robust anti-tumor activity while improving patient convenience and reducing side effects typically associated with more frequent intravenous treatments.

The PALOMA-2 trial, particularly its fully enrolled Cohort 5, evaluated the efficacy and safety of the Q4W (every four weeks) subcutaneous amivantamab in combination with lazertinib as a frontline therapeutic strategy for treatment-naïve patients diagnosed with EGFR Ex19del or L858R mutated advanced NSCLC. Amivantamab, a bispecific antibody targeting both EGFR and MET receptors, is designed to inhibit key proliferative and survival signaling pathways in tumor cells displaying these specific genetic alterations. Lazertinib, a potent third-generation EGFR tyrosine kinase inhibitor (TKI), complements this mechanism by selectively targeting mutant EGFR, thereby enhancing the therapeutic impact.

Among the 77 patients enrolled in the study, the median age was 63 years, reflecting a representative patient population, with demographic diversity including 68% female participants and 62% of Asian descent. Notably, 43% of patients presented with brain metastases at screening, emphasizing the real-world complexity and aggressiveness of EGFR mutation-positive NSCLC that necessitates effective systemic therapies capable of penetrating central nervous system compartments.

The dosing schedule analyzed in the trial revealed an impressive objective response rate (ORR) of 82% as assessed by investigators, which was corroborated by independent central review (ICR) confirming an ORR of 87%. These figures signify a substantial anti-cancer effect rarely matched in this heavily studied patient subgroup. Furthermore, the confirmed ORR remained high at 79% by investigator assessment and 83% by ICR. Median time to response was rapid as well, occurring at 8.1 weeks, highlighting the regimen’s ability to induce swift tumor regression.

Importantly, the median duration of response, progression-free survival (PFS), and overall survival metrics were not yet reached at the 6.5-month follow-up mark, suggesting durable benefits that warrant longer observation. The durability of response, coupled with high initial efficacy, reinforces the potential for this regimen to become a new standard of care option that balances therapeutic potency with quality of life considerations.

Safety data from the study underscore the regimen’s favorable tolerability profile. Administration-related reactions (ARRs), a common issue with antibody therapies, were observed in only 12% of participants, with a single Grade 3 or higher event reported, representing a notable reduction compared to prior intravenous or more frequent subcutaneous dosing methods. This reduction in high-grade ARRs signals an important step forward in minimizing treatment-related discomfort and adverse sequelae.

Common adverse events predominantly reflected the expected class effects of EGFR and MET pathway inhibition, including dermatologic manifestations such as paronychia and rash, as well as hypoalbuminemia. These toxicities were generally manageable and consistent with prior experience using these agents. Venous thromboembolic events (VTEs) appeared in 13% of patients but were limited to less severe grades, with no reports of Grade 3 or higher VTE complications, and bleeding events remained rare at a frequency of 1%, further cementing the regimen’s manageable safety profile.

Pharmacokinetic analysis revealed that mean plasma concentration levels of amivantamab with Q4W subcutaneous administration aligned closely with historical data from intravenous and every-two-week (Q2W) subcutaneous dosing schedules. This pharmacokinetic equivalence indicates that the prolonged dosing interval does not compromise drug exposure, adding mechanistic credence to the observed clinical efficacy and safety outcomes.

With just 8% of patients discontinuing therapy due to treatment-related adverse events, the Q4W administration regimen demonstrates not only clinical viability but also a meaningful enhancement of patient adherence potential—a critical factor in chronic cancer management. The subcutaneous route itself, compared to intravenous infusion, affords greater convenience for patients by reducing infusion chair time and associated resource utilization in outpatient oncology settings.

Dr. Susan Scott, leading investigator at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, emphasized that the trial’s data advocate for the incorporation of Q4W amivantamab dosing as a frontline strategy for EGFR-mutant NSCLC patients, underscoring that this less burdensome treatment model “offers a less burdensome treatment option without compromising efficacy.” According to her, the findings herald not only a therapeutic milestone but also a patient-centric evolution in lung cancer care, improving quality of life through simplified medication schedules.

This development is critically timely considering the ongoing global burden of lung cancer, as EGFR-driven NSCLC remains a prevalent and challenging disease entity with variable responses to targeted therapies. The flexibility and efficacy demonstrated by this subcutaneous Q4W dosing regimen open new horizons for therapeutic optimization and personalized cancer care paradigms.

The PALOMA-2 study’s positive outcomes resonate deeply within the research community, presenting an encouraging avenue for further exploration in subsequent phase trials and real-world clinical applications. The trial reinforces the growing consensus that targeted combinations leveraging antibody-based and kinase inhibitor modalities can deliver synergistic anticancer effects with manageable toxicity, a cornerstone principle in modern oncology innovation.

As the lung cancer field continues to evolve, the implications of these findings are profound: enabling effective control of tumor progression with improved patient experience may transform current treatment algorithms, particularly for the sizeable population of patients newly diagnosed with EGFR-mutant NSCLC, many of whom face rapidly advancing disease and complex clinical scenarios.

Looking ahead, longer-term follow-up and expanded patient cohorts will be essential to confirm the durability of response, overall survival benefits, and to further characterize the long-term safety profile of the Q4W amivantamab plus lazertinib combination. Still, the evidence amassed thus far provides a compelling rationale for healthcare providers to consider and advocate for subcutaneous amivantamab dosing strategies in future clinical practice guidelines.

In conclusion, the PALOMA-2 trial’s presentation at the 2025 WCLC stands as a landmark step forward in the quest to refine lung cancer therapeutics by integrating efficacy, convenience, and tolerability into new treatment paradigms that promise to improve outcomes for patients worldwide.


Subject of Research: Subcutaneous Amivantamab and Lazertinib Combination Therapy for Frontline Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Article Title: PALOMA-2 Trial Data Reveal Promising Efficacy and Safety of Once-Monthly Subcutaneous Amivantamab with Lazertinib in Untreated EGFR-Mutated NSCLC

News Publication Date: September 9, 2025

Web References: www.iaslc.org

Keywords: Lung cancer, NSCLC, EGFR mutation, amivantamab, lazertinib, targeted therapy, subcutaneous administration, PALOMA-2, clinical trial, EGFR Ex19del, L858R mutation, quality of life

Tags: advanced non-small cell lung canceranti-tumor activitybispecific antibody therapyEGFR-mutated NSCLC treatmentfrontline therapy for lung cancer.lazertinib combination therapynovel cancer dosing regimenPALOMA-2 studypatient convenience in cancer treatmentside effects reduction in chemotherapysubcutaneous amivantamabthird-generation EGFR TKI
Share26Tweet16
Previous Post

Key Tips for Multi-Phase PMCT Angiography Interpretation

Next Post

Breakthrough 3D Real-Time Imaging Reveals Hydrogen’s Impact on Stainless Steel Defects, Paving the Way for a Safer Hydrogen Economy

Related Posts

blank
Cancer

AI vs. Tumor Boards: Benchmarking Sarcoma Treatments

September 10, 2025
blank
Cancer

Brain Lung Cancer Cells Create Electrical Links with Neurons, Driving Tumor Growth

September 10, 2025
blank
Cancer

Southampton Team Pioneers Next-Generation Cancer Treatments

September 10, 2025
blank
Cancer

Faster Diagnostic Scans Could Revolutionize Prostate Cancer Detection for Millions

September 10, 2025
blank
Cancer

UMD Researchers Leverage AI to Enhance Confidence in HPV Vaccination

September 10, 2025
blank
Cancer

Laparoscopic D2 vs D2 Plus CME Outcomes

September 10, 2025
Next Post
blank

Breakthrough 3D Real-Time Imaging Reveals Hydrogen's Impact on Stainless Steel Defects, Paving the Way for a Safer Hydrogen Economy

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27547 shares
    Share 11016 Tweet 6885
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    963 shares
    Share 385 Tweet 241
  • Bee body mass, pathogens and local climate influence heat tolerance

    643 shares
    Share 257 Tweet 161
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    511 shares
    Share 204 Tweet 128
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    314 shares
    Share 126 Tweet 79
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Lu–Hf Isotopes Reveal Ryugu’s Ancient Fluid Flow
  • Study from USF Explores the Effects of Menopause on Women’s Voices and Its Significance
  • Advancing Sustainability: Green Marketing and TQM in Nursing
  • Eye and Blood Protein Shows Strong Link to Cognitive Performance, Study Finds

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Blog
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 5,182 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading